A Study to Assess Safety and Efficacy of Perampanel in Indian Participants as an Adjunctive Treatment in Partial Onset Seizures With or Without Secondary Generalized Seizures in Participants With Epilepsy Aged 12 Years or Older
A Prospective, Multicenter, Post-marketing Surveillance to Assess Safety & Efficacy of Perampanel in Indian Patients as An Adjunctive Treatment in Partial Onset Seizures With or Without Secondary Generalized Seizures in Patients With Epilepsy Aged 12 Years or Older
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Delhi, India
- Shri Ganga Ram Hospital
-
Jaipur, India
- Advance Neurology & Superspeciality Hospital
-
-
Karnataka
-
Bengaluru, Karnataka, India, 560060
- BGS Gleneagles Global Hospitals
-
-
Maharashtra
-
Mumbai, Maharashtra, India, 400012
- Seth G S Medical College & KEM Hospital
-
Nagpur, Maharashtra, India, 440012
- Getwell Hospital and Research Institute
-
Nagpur, Maharashtra, India, 440012
- Brain Clinic, Jasleen Hospital
-
Pune, Maharashtra, India, 411004
- Deenanath Mangeshkar Hospital and Research Centre
-
Pune, Maharashtra, India, 411057
- Lifepoint Multispecialty Hospital
-
-
Telangana
-
Hyderabad, Telangana, India, 500082
- Nizam's Institute of Medical Sciences Department of Neurology
-
-
Uttar Pradesh
-
Lucknow, Uttar Pradesh, India, 226014
- Sanjay Gandhi Post Graduate Institute of Medical Sciences
-
-
West Bengal
-
Kolkata, West Bengal, India, 700026
- Ramakrishna mission seva pratisthan vivekananda institute of medical sciences
-
Kolkata, West Bengal, India, 700068
- Sri Aurobindo Seva Kendra
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Participants prescribed perampanel for the adjunctive treatment of partial onset seizures based on independent clinical judgment of treating physicians.
Exclusion Criteria:
- Participation in another study involving administration of an investigational drug or device whilst participating in this observational study.
- Hypersensitivity [allergic] to perampanel.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Perampanel
Participants receiving perampanel tablets, orally according to prescribing information and the treating physician's clinical judgment will be observed prospectively for up to 6 months or participant withdrawal, whichever occurs first.
|
Perampanel tablets.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of Participants Reporting one or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time Frame: Up to 6 months
|
Up to 6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percent Change From Baseline in Seizure Frequency per 28 days During the Treatment Period
Time Frame: Up to 6 months
|
Up to 6 months
|
|
Percentage of Participants Who Experienced at Least 50 Percent Reduction From Baseline in Seizure Frequency During the Treatment Period
Time Frame: Up to 6 months
|
Up to 6 months
|
|
Percentage of Participants Who Achieved a Seizure-free Status During the Treatment Period
Time Frame: At 3 months and 6 months
|
At 3 months and 6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- E2007-M091-508
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.